Equitec Proprietary Markets, LLC Blueprint Medicines Corp Transaction History
Equitec Proprietary Markets, LLC
- $102 Million
- Q2 2025
A detailed history of Equitec Proprietary Markets, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Equitec Proprietary Markets, LLC holds 92,500 shares of BPMC stock, worth $12 Million. This represents 11.57% of its overall portfolio holdings.
Number of Shares
92,500Holding current value
$12 Million% of portfolio
11.57%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
379Shares Held
68.1MCall Options Held
1.54MPut Options Held
1.21M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$860 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$701 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$498 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$398 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...